Stanford, California 94305

  • Multiple Myeloma


To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Study summary:

To assess the toxicity and efficacy of sequentially administered high dose cyclophosphamide and VP-16 followed by total body irradiation or BCNU and high dose mephalan and autologous stem cell rescue in the treatment of multiple myeloma.


Inclusion Criteria:- received cytoreduction prior to transplant - adequate organ function Exclusion Criteria:- previous transplant - smoldering MM or benign monoclonal gammopathy



Primary Contact:

Principal Investigator
Sally Arai
Stanford University

Backup Contact:


Location Contact:

Stanford, California 94305
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.